Avidity Biosciences (RNA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.55 (-1.43%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Avidity Biosciences (RNA)
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Key Insights

Critical company metrics and information
  • Share Price

    $37.93
  • Market Cap

    $4.53 Billion
  • Total Outstanding Shares

    119.31 Million Shares
  • Total Employees

    253
  • Dividend

    No dividend
  • IPO Date

    June 12, 2020
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.aviditybiosciences.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$1.21 Billion
Net Cash Flow From Financing Activities, Continuing$1.21 Billion
Net Cash Flow, Continuing$287.04 Million
Net Cash Flow From Investing Activities, Continuing$-738.99 Million
Net Cash Flow From Operating Activities$-184.50 Million
Net Cash Flow From Investing Activities$-738.99 Million
Net Cash Flow From Operating Activities, Continuing$-184.50 Million
Net Cash Flow$287.04 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Nonoperating Income/Loss$44.20 Million
Revenues$10.12 Million
Operating Expenses$334.81 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-280.49 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$-280.49 Million
Research and Development$260.79 Million
Income/Loss From Continuing Operations Before Tax$-197.75 Million
Operating Income/Loss$-324.69 Million
Benefits Costs and Expenses$290.61 Million
Basic Average Shares$318.54 Million
Net Income/Loss Available To Common Stockholders, Basic$-280.49 Million
Costs And Expenses$290.61 Million
Diluted Average Shares$318.54 Million
Other Operating Expenses$74.02 Million
Diluted Earnings Per Share$2.89
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Earnings Per Share$2.89
Net Income/Loss$-280.49 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$1.64 Billion
Other Non-current Assets$9.41 Million
Fixed Assets$9.49 Million
Other Current Assets$7.80 Million
Equity Attributable To Noncontrolling Interest$0.00
Cash$1.60 Billion
Equity Attributable To Parent$1.50 Billion
Noncurrent Liabilities$46.06 Million
Other Current Liabilities$83.67 Million
Liabilities$137.39 Million
Assets$1.64 Billion
Current Liabilities$91.33 Million
Accounts Payable$7.66 Million
Equity$1.50 Billion
Current Assets$1.62 Billion
Prepaid Expenses$14.06 Million
Noncurrent Assets$18.91 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.